NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $11.59 -0.20 (-1.70%) Closing price 04:00 PM EasternExtended Trading$11.60 +0.02 (+0.13%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CorMedix Stock (NASDAQ:CRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CorMedix alerts:Sign Up Key Stats Today's Range$11.45▼$11.8650-Day Range$9.03▼$16.5652-Week Range$3.61▼$17.43Volume1.98 million shsAverage Volume1.34 million shsMarket Capitalization$786.03 millionP/E Ratio52.68Dividend YieldN/APrice Target$17.14Consensus RatingModerate Buy Company Overview CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Read More CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreCRMD MarketRank™: CorMedix scored higher than 47% of companies evaluated by MarketBeat, and ranked 612th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CorMedix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is 52.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.64.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is 52.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 18.70.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.37% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in CorMedix has recently increased by 0.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.37% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in CorMedix has recently increased by 0.70%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.52 News SentimentCorMedix has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for CorMedix this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for CRMD on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Stock News HeadlinesEquities Analysts Offer Predictions for CorMedix Q2 EarningsJuly 2 at 2:18 AM | americanbankingnews.comD. Boral Capital Downgrades CorMedix (CRMD)July 1 at 2:37 AM | msn.comForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.July 2 at 2:00 AM | Brownstone Research (Ad)HC Wainwright & Co. Initiates Coverage of CorMedix (CRMD) with Buy RecommendationJune 30 at 4:35 PM | msn.comCorMedix Seems Significantly UndervaluedJune 30 at 3:01 PM | seekingalpha.comCorMedix Analyst Says Investors Could Be Further RewardedJune 30 at 3:01 PM | benzinga.comCorMedix Shares Drop After $85 Million Public Offering PricesJune 27, 2025 | marketwatch.comUpgrade: Analysts Just Made A Captivating Increase To Their CorMedix Inc. (NASDAQ:CRMD) ForecastsJune 27, 2025 | finance.yahoo.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $8.10 on January 1st, 2025. Since then, CRMD shares have increased by 43.1% and is now trading at $11.59. View the best growth stocks for 2025 here. How were CorMedix's earnings last quarter? CorMedix Inc (NASDAQ:CRMD) issued its earnings results on Tuesday, May, 6th. The company reported $0.30 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.05. The business earned $39.08 million during the quarter, compared to analyst estimates of $38.90 million. CorMedix had a net margin of 20.81% and a trailing twelve-month return on equity of 22.57%. Read the conference call transcript. When did CorMedix's stock split? CorMedix shares reverse split on Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR). Company Calendar Last Earnings5/06/2025Today7/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$17.14 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+49.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.22 Trailing P/E Ratio52.13 Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.93 million Net Margins20.81% Pretax Margin20.81% Return on Equity22.57% Return on Assets17.02% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio3.99 Sales & Book Value Annual Sales$43.47 million Price / Sales17.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book8.20Miscellaneous Outstanding Shares67,820,000Free Float64,230,000Market Cap$778.23 million OptionableOptionable Beta1.58 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CRMD) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.